Day: July 10, 2024

HOUSTON, July 10, 2024 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) today announced that it will release its financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 31, 2024. The Company will host a webcast and conference call to discuss the results on Thursday, August 1, 2024, at 8:30 A.M. Eastern Time. The call will be led by Dave Holeman, Chief Executive Officer. The webcast and conference call access information is as follows:Dial-in number for domestic participants: 1-877-407-0784Dial-in number for international participants: 1-201-689-8560Passcode: 13742563   The conference call will be recorded, and a telephone replay will be available through August 15, 2024. Replay access information is as follows:Replay number for domestic...

LAS VEGAS, July 10, 2024 (GLOBE NEWSWIRE) — Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a leader in artificial intelligence (AI) technology specializing in cutting edge AI and data center infrastructure solutions, today announced its planned state-of-the-art data centers, outfitted with immersible AI supercomputer servers, will address a number of unmet needs in the AI and big data industry’s rapid growth, while answering key sustainability and infrastructure concerns arising in the communities that support data centers. For the needs of AI and big data companies, Avant expects to deliver more data capabilities, specialized attention to each client, and a most cost-effective option. Meanwhile, Avant plans to introduce data centers with a smaller footprint and that draw less energy from the local community,...

SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentation section approximately two hours after the call concludes. ABOUT LEGEND BIOTECH Legend Biotech is a global biotechnology company dedicated to treating, and one day curing,...

Latest technology advancements also enhance capabilities in core industries, including logistics and energy WATERTOWN, Mass., July 10, 2024 (GLOBE NEWSWIRE) — Spectaire Holdings Inc. (NASDAQ: SPEC) (“Spectaire” or the “Company”), a pioneer in environmental measurement technology, today announced the upcoming release of AireCore 2.0, the next generation in micro mass spectrometry. Scheduled for shipment in Q1 2025, AireCore 2.0 will feature Double Focusing Mass Spectrometry (DFMS), a significant advancement over the previous Single Focusing Mass Spectrometry (SFMS) technology, positioning the Company for new revenue streams and substantial market opportunities. Key Enhancements with DFMS:Enhanced Resolution and Accuracy: DFMS technology allows for greater separation of ions with similar mass-to-charge ratios, providing higher...

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 4292675. The call will also be available via live or archived webcast on the “Investors” section of the Maravai web site at https://investors.maravai.com. About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies,...

VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the second quarter after market close on Wednesday, August 14, 2024. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better...

CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced it will participate in the Association for Research in Vision and Ophthalmology Special Interest Group (ARVO SIG) panel and the American Society of Retina Specialists (ASRS) 42nd Annual Scientific Meeting, to highlight the potential of its lead oral candidate in development for diabetic retinopathy (DR). APX3330 is an oral small-molecule inhibitor...

CHICAGO, July 10, 2024 (GLOBE NEWSWIRE) — Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”) today announced that it will release its second quarter 2024 results after the market close on Wednesday, July 31, 2024, followed by a conference call at 6:00 pm Eastern Time (5:00 pm Central Time) to discuss the results. RSI’s earnings press release and related materials will be available at ir.rushstreetinteractive.com. To listen to the audio webcast and live Q&A, please visit RSI’s investor relations website at ir.rushstreetinteractive.com. Interested parties may also dial 1-833-470-1428 (Toll Free) or 1-404-975-4839 (Local) or, for international callers, 1-929-526-1599. The conference call access code is 340374. An audio replay of the webcast will be available on RSI’s investor relations website shortly after the call until at least...

Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announces promising preclinical results for its investigational candidate, certepetide (formerly LSTA1). The data, presented in a poster by Dr. Dan G. Duda of Massachusetts General Hospital at the 2024 Cholangiocarcinoma Foundation Annual Conference, showed that certepetide combined with standard-of-care chemotherapy and immunotherapy improved survival in mice with intrahepatic cholangiocarcinoma. These findings suggest potential benefits for human patients with this aggressive...

Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathway and future development plans following positive feedback from the FDA to move forward with chronic HBV DNA suppression as the primary efficacy endpoint Scheduled for Thursday, July 18, 2024 at 3:00pm ET/12:00pm PTSOUTH SAN FRANCISCO, Calif., July 10, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Johns Hopkins University School of Medicine, to discuss the unmet need and current treatment landscape for patients with chronic hepatitis B (CHB), positive...